CD274 and metastatic neoplasm: Keynote 024 is Phase 3, global, multicenter, open-label, 1:1 ran-domized trial comparing fixed dose pembrolizumab 200 mg every 3 weeks (n = 154) to the investigator’s choice of five different platinum-based chemotherapy regimens (n = 150) in patients with both squamous and non-squamous Stage IV NSCLC who have not received prior systemic therapy for their metastatic disease and have PD-L1 expression on ≥50% of TCs.